Graft Polymer (UK) PLC (GB:GPL) has released an update.
Graft Polymer (UK) PLC has completed an operational review and entered into its first commercial collaboration with Awakn Life Sciences Corp., focusing on the development of novel therapeutics for trauma-related mental health disorders. This strategic partnership leverages Graft Polymer’s drug delivery systems with Awakn’s small molecule therapeutics expertise, aiming to address the sizable market for conditions like PTSD. The collaboration, which is seen as potentially creating significant shareholder value, involves an initial £300,000 investment by Graft Polymer for a 40% stake in the future net income of Awakn’s program.
For further insights into GB:GPL stock, check out TipRanks’ Stock Analysis page.
